Changes to the Executive Management of Orphazyme – Anders Vadsholt to be appointed CEO
31 janv. 2022 11h00 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 03/2022Inside informationwww.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, January 31, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme”...
Notice to convene Extraordinary General Meeting
24 janv. 2022 16h15 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 02/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, January 24, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (the “Company”), a...
Orphazyme updates 2021 financial outlook
18 janv. 2022 16h15 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 01/2022Inside information Company Registration No. 32266355 Net revenue range narrowed to DKK 35 – 37 millionOperating expenses lowered to DKK 665 – 675...
Orphazyme announces changes to the Board of Directors
09 déc. 2021 00h45 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 27/2021Company Registration No. 32266355 Copenhagen – December 9, 2021 – Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage biopharmaceutical...
Financial Calendar 2022
19 nov. 2021 03h06 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 26/2021www.orphazyme.comCompany Registration No. 32266355 Copenhagen – November 19, 2021 – Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a...
Orphazyme establishes a U.S. At-the-Market Offering Program with Cowen
04 nov. 2021 08h22 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 25/2021Company Registration No. 32266355 Copenhagen – November 4, 2021 – Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage biopharmaceutical...
Orphazyme provides regulatory update following Type A meeting with FDA on arimoclomol in Niemann-Pick disease type C
31 oct. 2021 16h00 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 24/2021Inside informationCompany Registration No. 32266355 Progress made in understanding potential resolution of topics outlined in Complete Response...
Modified long-term share-based incentive program for 2021
07 oct. 2021 02h40 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 23/2021Company Registration No. 32266355 Copenhagen, Denmark, October 7, 2021 – Orphazyme A/S (ORPHA.CO (DK); ORPH (US)), a late-stage...
Orphazyme provides regulatory and financial updates
05 oct. 2021 02h55 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 22/2021Company Registration No. 32266355 Copenhagen – October 5, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today...
Orphazyme reports business highlights and financial results in Interim Report First Half 2021
31 août 2021 01h00 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 21/2021CVR No.: 32266355 Copenhagen, Denmark, August 31, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage biopharmaceutical company, today...